海南海药创新药研发取得重大进展

Core Insights - Hainan Haiyao has made significant progress in the development of two innovative drugs: Fluorofenidone capsules for organ fibrosis diseases and Paenagabin tablets for neurological disorders [2][3] - Fluorofenidone capsules have been included in the National Medical Products Administration's list of breakthrough therapies as of February 2025, with Phase I clinical trials confirming safety and tolerability, and Phase II trials achieving primary endpoints [2] - Paenagabin tablets, a new generation KCNQ potassium channel agonist, have shown excellent safety and tolerability in Phase I trials, with ongoing Phase IIa studies [2] Company Strategy - Hainan Haiyao is committed to enhancing its strategic layout in emerging industries, focusing on the development of innovative drugs and increasing R&D investment [3] - The company aims to transform from a "generic-innovative combination" model to an "innovation-driven" development approach, positioning itself as a benchmark for innovative development in Hainan Free Trade Port [3] - Future plans include leveraging the advantages of Hainan Free Trade Port's biopharmaceutical policies to introduce high-end foreign medical products and promote the company's innovative products internationally [3]